SAN DIEGO-The San Diego life sciences sector has moved at a slow pace over the last few quarters with a low transaction volume, according to a report released by Cushman & Wakefield's Global Life Sciences Practice Group. However, mergers and acquisitions activity, initial public offerings and funding activity has been on the rise.
San Diego companies are the third-most invested in, following behind San Francisco and Boston, according to a report by PricewaterhouseCoopers LLP and the National Venture Capital. Venture capitalist investments are up 26% from one year ago, with $1.8 billion invested in 174 life science companies. In addition, there is positive news on the exit front, in IPOs, corporate partnerships and M&A.
“M&A activity was extremely high in 2012, with such acquisitions as Amylin ($7 billion), Gen-Probe ($3.7 billion), and Ardea ($1.26 billion),” says Greg Bisconti, senior director of C&W's Global Life Sciences Practice Group. “M&A activity continues into 2013 with the $175 million acquisition of Althea Technologies by Ajinomoto announced in early March and the recent announcement of Verenium entering an agreement to be acquired by chemicals giant BASF. In the first quarter, Thermo Fisher Scientific revealed its intent to purchase Life Technologies for $13.6 billion, or $76 per share. Another big deal was the Johnson & Johnson acquisition of Aragon Pharmaceuticals for up to $1 billion, which included an upfront cash payment of $650 million.”
Throughout 2013, San Diego has seen limited quality lab space availability as well as limited major transaction activity. In 2012, the life sciences sector had an average of 213,000 square feet of leasing activity per quarter. The first three quarters of 2013 averaged just 158,400 square feet per quarter.
San Diego saw vacancy rates in the 10% range throughout the first and second quarters of 2013 with a slight rise in the third quarter to 11%, says the report. Due to the slow start in 2013, owners remain motivated and the major life science landlords are continuing to upgrade their buildings.
“We expect rates to rise in the coming quarters due to decreasing vacancy, making this a good time for tenants to assess their current facility to decide if it will meet their long term needs,” says Brent Jacobs, executive director of C&W's Global Life Sciences Practice Group. “This is also an ideal time for local entrepreneurs to grow and new companies to arise.”
Continue Reading for Free
Register and gain access to:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.